Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Incyte Genomics Inc (INCY) SEC filings page on Stock Titan aggregates regulatory documents for Incyte Corporation, a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. These filings provide structured insight into how the company reports its financial condition, governance changes and material events to the U.S. Securities and Exchange Commission.
Incyte’s common stock is listed on The Nasdaq Stock Market LLC under the symbol INCY, as disclosed in Form 8‑K reports. Investors can review current reports on Form 8‑K that cover topics such as quarterly financial results, executive and board transitions, inducement equity awards and key corporate agreements. For example, recent 8‑Ks describe leadership changes in the chief executive officer and chief financial officer roles, transition and employment agreements, and announcements of quarterly earnings press releases.
Alongside 8‑Ks, users can access Incyte’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) to understand segment focus, risk factors, research and development priorities, and other disclosures that frame the company’s oncology and immunology strategy. These periodic reports typically detail the status of marketed products and pipeline programs, capital structure and significant accounting policies.
For those tracking management incentives and ownership, the filings page also links to insider transaction reports on Form 4 and related beneficial ownership disclosures, where present in EDGAR. These documents show grants of stock options, restricted stock units and performance shares, such as inducement awards and executive compensation packages referenced in Incyte’s current reports.
Stock Titan enhances this information by providing AI-powered summaries that explain the key points of lengthy filings, highlight notable changes and help readers interpret complex legal and financial language. Real‑time updates from EDGAR ensure that new INCY filings—whether earnings‑related, governance‑related or tied to material clinical and commercial developments—are quickly reflected, allowing investors, researchers and other stakeholders to review the underlying documents and AI insights in one place.
Incyte Corporation filed a current report stating that it has released financial results for its third fiscal quarter ended September 30, 2025. The company furnished the full text of its earnings press release as Exhibit 99.1, dated October 28, 2025. The report is presented as routine financial disclosure under the item covering results of operations and financial condition.
Incyte (INCY) reported an insider transaction by its EVP & General Counsel. On 10/15/2025, the officer exercised 277 employee stock options at a $64.25 exercise price and sold 277 shares of common stock at $85.13.
Following the transactions, the officer beneficially owned 26,569 shares directly, which includes an aggregate of 25,913 shares issuable from previously reported unvested RSUs and earned performance units. Derivative securities beneficially owned after the transactions totaled 9,161 options. The reported option grant expires on 07/14/2034 and vests in installments as disclosed.
Sheila A. Denton, EVP & General Counsel of Incyte Corp (INCY), reported multiple transactions on
Incyte Corporation (INCY) submitted a Form 144 notifying a proposed sale of 3,501 restricted shares valued at $299,464.34, to be executed through Morgan Stanley Smith Barney LLC on 10/03/2025 on NASDAQ. The shares were acquired as restricted stock from the issuer on 10/02/2025 and the filer reports 195,276,145 shares outstanding for the issuer.
The filing lists prior insider sales by Sheila Denton over the past three months totaling 6,165 shares across seven transactions, with gross proceeds shown for each sale (largest single prior sale: 3,330 shares for $232,633.80 on 07/15/2025). The notice includes the standard signature representation that the seller has no undisclosed material adverse information and names the executing broker and address.
Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte Corp (INCY), reported a disposition of company shares on 10/01/2025. The filing shows 1,569 shares of common stock were disposed of at a price of $86.70 per share under transaction code F, and the reporting person remains the beneficial owner of 65,819 shares following the transaction. The filing explains the 1,569 shares represent shares withheld automatically by the issuer to satisfy tax-withholding obligations associated with the settlement of previously reported restricted stock units.
The report also notes that of the remaining position, 59,858 shares are issuable pursuant to previously reported restricted stock units that have not vested. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025.
Heeson Lee, EVP and Head of Incyte International, filed a Form 4 reporting changes in beneficial ownership of INCY common stock. On 10/01/2025 the filing shows 463 shares were disposed of (reported under Code F) at a price of $86.7 per share to satisfy tax withholding obligations tied to previously granted restricted stock units. After the reported transaction the filing shows beneficial ownership of 32,315 shares; the filer discloses that this total includes 26,167 shares issuable under previously reported unvested RSUs. The form is signed by an attorney-in-fact on 10/03/2025.
Incyte Corporation reported a leadership change in its finance organization. The Board of Directors appointed Thomas Tray, currently Vice President, Finance and Chief Accounting Officer, to also serve as the company’s principal financial officer, effective as of September 16, 2025.
Tray, age 48, has been with Incyte since 2005, starting as Manager of External Reporting and later serving as Vice President and Controller before his current roles. He holds a B.S. in Accounting from Mount Saint Mary’s University and an Executive MBA in Pharmaceutical Marketing from Saint Joseph’s University. The company states there are no special arrangements related to his appointment, no family relationships with directors or executive officers, and no material related-party transactions requiring disclosure.
Incyte Corp director Paul J. Clancy acquired 285 shares of Incyte common stock on 09/30/2025 at a price of $84.81 per share through restricted shares issued in lieu of quarterly director retainer fees under the company’s Amended and Restated 2010 Stock Incentive Plan; those restricted shares are reported as fully vested.
Following this transaction, the reporting person beneficially owns 23,235 shares in total, which includes an aggregate of 2,518 shares issuable upon previously reported restricted stock units that have not vested.
Edmund Harrigan, a director of Incyte Corp (INCY), acquired 289 shares of common stock on 09/30/2025 at a price of $84.81 per share. The shares were issued as restricted shares under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of a quarterly director retainer, and the filing states the restricted shares are fully vested. After this transaction, the reporting person beneficially owns 20,608 shares, which includes 2,518 shares issuable under previously reported restricted stock units that have not vested. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Form 144 notice for INCY (Incyte Corp): An individual, Sheila Denton, filed a proposed sale of 599 common shares to be executed through Morgan Stanley Smith Barney LLC on 10/02/2025 on the NASDAQ. The filing shows those 599 shares were acquired on 10/02/2025 by exercising stock options and paid in cash. The form lists six prior open-market sales by the same person during Jul–Sep 2025 totaling 6,165 shares sold across multiple dates with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information.